HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $5 Price Target
Benzinga Newsdesk 6 months ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $5 price target.
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $5 price target.